These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Proteome screening of pleural effusions identifies galectin 1 as a diagnostic biomarker and highlights several prognostic biomarkers for malignant mesothelioma. Mundt F; Johansson HJ; Forshed J; Arslan S; Metintas M; Dobra K; Lehtiö J; Hjerpe A Mol Cell Proteomics; 2014 Mar; 13(3):701-15. PubMed ID: 24361865 [TBL] [Abstract][Full Text] [Related]
5. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology. Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183 [TBL] [Abstract][Full Text] [Related]
6. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. Creaney J; Dick IM; Segal A; Musk AW; Robinson BW Lung Cancer; 2013 Dec; 82(3):491-8. PubMed ID: 24161718 [TBL] [Abstract][Full Text] [Related]
7. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037 [TBL] [Abstract][Full Text] [Related]
8. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis. Gao R; Wang F; Wang Z; Wu Y; Xu L; Qin Y; Shi H; Tong Z Medicine (Baltimore); 2019 Apr; 98(14):e14979. PubMed ID: 30946324 [TBL] [Abstract][Full Text] [Related]
10. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881 [TBL] [Abstract][Full Text] [Related]
11. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982 [TBL] [Abstract][Full Text] [Related]
12. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308 [TBL] [Abstract][Full Text] [Related]
13. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930 [TBL] [Abstract][Full Text] [Related]
14. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993 [TBL] [Abstract][Full Text] [Related]
15. Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion. Kishimoto T; Kojima Y; Fujimoto N Sci Rep; 2021 Jun; 11(1):12965. PubMed ID: 34155270 [TBL] [Abstract][Full Text] [Related]
16. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications. Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072 [TBL] [Abstract][Full Text] [Related]
17. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma. Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810 [TBL] [Abstract][Full Text] [Related]
18. Comparison of mesothelin and fibulin-3 in pleural fluid and serum as markers in malignant mesothelioma. Creaney J; Dick IM; Robinson BW Curr Opin Pulm Med; 2015 Jul; 21(4):352-6. PubMed ID: 26016578 [TBL] [Abstract][Full Text] [Related]
19. ATG5 as biomarker for early detection of malignant mesothelioma. Tomasetti M; Monaco F; Strogovets O; Volpini L; Valentino M; Amati M; Neuzil J; Santarelli L BMC Res Notes; 2023 Apr; 16(1):61. PubMed ID: 37095543 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. Mundt F; Heidari-Hamedani G; Nilsonne G; Metintas M; Hjerpe A; Dobra K Biomed Res Int; 2014; 2014():419853. PubMed ID: 25147801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]